GVAX : Cell Genesys : Vaccine

Granulocyte-Macrophage Colony-Stimulating Factor Gene-Modified Autologous Tumor Vaccines in NSCLC (JNCI Cancer Spectrum)
Reports encouraging results of a phase I/II multicenter trial in patients with NSCLC of the feasibility, safety and efficacy of vaccination with autologous tumor cells genetically modified with an adenoviral vector (Ad-GM) to secrete human granulocyte-macrophage colony-stimulating factor (GM-CSF). [2/04]

GVAX Lung Cancer Vaccine (Cell Genesys)
Describes GVAX, a patient-specific vaccine designed to induce a systemic immune response against the patient's lung cancer. Reviews previous and ongoing clinical trials. [2003]

Cell Genesys Launches Expanded Phase II Trial of GVAX Lung Cancer Vaccine (Cell Genesys)
Announcement of multicenter Phase II clinical trial of GVAX vaccine in 75 patients with advanced NSCLC. Patients will be randomized to received GVAX with or without low-dose cyclophosphamide, a chemotherapy drug that has been shown to enhance the immune response. Also announced is a second expanded Phase II GVAX trial in patients with BAC, a sub-type of NSCLC which may be particularly responsive to GVAX. [4/03]

Vaccination with Irradiated Autologous Tumor Cells Engineered to Secrete GM-CSF Augments Antitumor Activity in Some Patients with Metastatic NSCLC (Journal of Clinical Oncology)
Reports results of a phase I study that found vaccination with irradiated autologous NSCLC cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances antitumor immunity in some patients with metastatic NSCLC. [2/03]

GVAX Phase I/II Data Promising Against Lung Cancer (cancernetwork.com)
Discusses results from the multicenter Phase I/II GVAX lung cancer vaccine trial. The trial tested a patient-specific form of the vaccine that was made directly from patient tumor biopsies in 33 NSCLC patients. Findings showed increased survival over docetaxel (the approved 2nd line chemotherapy) and best supportive care. Three patients (two with BAC) with advanced disease achieved durable complete responses. Additional trials are planned. [6/02]